All In Biotech

Drug Trial Radar · NCT05877547

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 381 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

381

Actual

Start

Jun 23, 2023

Primary completion

Dec 29, 2025

Study completion Dec 29, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.

Conditions

  • Non-alcoholic Fatty Liver Disease
  • Fatty Liver, Nonalcoholic
  • NAFLD
  • Nonalcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis

Interventions

  • EfinopegdutideDrug

    Subcutaneous (SC) injection in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg

  • SemaglutideDrug

    SC injection in a dose-escalation regimen of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg

  • PlaceboDrug

    SC injection of matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52Time frame: Week 52
  2. Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to 60 weeks
  3. Percentage of Participants Discontinuing Study Medication Due to an AETime frame: Up to 52 weeks

Locations

175 sites in 26 countries. Site status is shown where the registry gives one.

  • The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3

    Chandler, Arizona

  • The Institute for Liver Health II dba Arizona Clinical Trials - Peoria ( Site 3289)

    Peoria, Arizona

  • The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 3218)

    Tucson, Arizona

  • Del Sol Research Management, LLC ( Site 3211)

    Tucson, Arizona

  • Om Research - Apple Valley ( Site 3244)

    Apple Valley, California

  • Om Research LLC ( Site 3245)

    Camarillo, California

  • Velocity Clinical Research, Gardena ( Site 3225)

    Gardena, California

  • Velocity Clinical Research, Huntington Park ( Site 3217)

    Huntington Park, California

  • Velocity Clinical Research, San Diego ( Site 3226)

    La Mesa, California

  • Om Research LLC ( Site 3229)

    Lancaster, California

  • Velocity Clinical Research, Westlake ( Site 3216)

    Los Angeles, California

  • Velocity Clinical Research, Panorama City ( Site 3214)

    Panorama City, California

  • California Liver Research Institute ( Site 3232)

    Pasadena, California

  • Clinical Trials Research ( Site 3230)

    Sacramento, California

  • Excel Medical Clinical Trials ( Site 3246)

    Boca Raton, Florida

  • Synergy Healthcare ( Site 3286)

    Bradenton, Florida

  • Synergy Healthcare LLC ( Site 3290)

    Brandon, Florida

  • Top Medical Research ( Site 3209)

    Cutler Bay, Florida

  • Covenant Metabolic Specialists, LLC ( Site 3231)

    Fort Myers, Florida

  • Velocity Clinical Research, Hallandale Beach ( Site 3241)

    Hallandale, Florida

  • Indago Research & Health Center, Inc ( Site 3207)

    Hialeah, Florida

  • Sweet Hope Research Specialty, Inc-Research ( Site 3200)

    Hialeah, Florida

  • Florida Research Institute ( Site 3243)

    Lakewood Rch, Florida

  • Genoma Research Group ( Site 3242)

    Miami, Florida

  • Floridian Clinical Research, LLC ( Site 3203)

    Miami Lakes, Florida

  • Southeast Clinical Research Center ( Site 3288)

    Dalton, Georgia

  • Eagle Clinical Research ( Site 3233)

    Chicago, Illinois

  • University of Iowa ( Site 3213)

    Iowa City, Iowa

  • Kansas City Research Institute ( Site 3249)

    Kansas City, Missouri

  • The Machuca Foundation ( Site 3234)

    Las Vegas, Nevada

  • Velocity Clinical Research, Syracuse ( Site 3227)

    East Syracuse, New York

  • New York Gastroenterology Associates ( Site 3252)

    New York, New York

  • Velocity Clinical Research, Cincinnati ( Site 3237)

    Cincinnati, Ohio

  • Velocity Clinical Research, Providence ( Site 3222)

    East Greenwich, Rhode Island

  • Velocity Clinical Research, Austin ( Site 3235)

    Austin, Texas

  • South Texas Research Institute - Brownsville ( Site 3285)

    Brownsville, Texas

  • Velocity Clinical Research, Dallas ( Site 3220)

    Dallas, Texas

  • Houston Research Institute ( Site 3262)

    Houston, Texas

  • American Research Corporation ( Site 3202)

    San Antonio, Texas

  • Pinnacle Clinical Research ( Site 3284)

    San Antonio, Texas

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.